Altimmune, Inc. (ALT)

Altimmune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	63.01	43.76	36.93	135.12	111.1	190.3
Short-Term Investments	263.27	229.7	94.97	62.7	73.78	-
Cash & Short-Term Investments	326.28	273.46	131.89	197.82	184.88	190.3
Cash Growth	78.19%	107.34%	-33.33%	7.00%	-2.85%	-11.87%
Accounts Receivable	0.04	1.22	0.54	1.11	0.17	0.43
Other Receivables	3.3	0.52	2.57	3.74	2.37	5.41
Receivables	3.34	1.74	3.12	4.85	2.54	5.84
Prepaid Expenses	4.95	2.76	2.2	6.92	5.36	7.95
Restricted Cash	0.04	0.04	0.04	0.04	0.03	0.03
Other Current Assets	0.2	0.2	-	-	-	-
Total Current Assets	334.82	278.19	137.25	209.63	192.81	204.13
Property, Plant & Equipment	0.15	1.74	2.05	1.01	1.68	2.25
Other Intangible Assets	-	-	-	-	12.42	12.42
Other Long-Term Assets	-	-	-	-	0.02	0.07
Total Assets	527.21	279.93	139.31	210.64	206.93	218.87

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.27	2.72	0.21	2.07	4.8	2.03
Accrued Expenses	10.96	12.02	9.98	9.58	10.63	9.74
Current Portion of Leases	0.27	0.26	0.28	0.5	0.45	0.41
Current Income Taxes Payable	-	-	-	-	1.17	-
Other Current Liabilities	-	-	-	-	-	6.09
Total Current Liabilities	12.5	15	10.47	12.14	17.05	18.28
Long-Term Debt	34.74	34.29	-	-	-	-
Long-Term Leases	1	1.15	1.4	0.18	0.67	1.12
Long-Term Unearned Revenue	0.15	0.16	0.16	0.16	0.25	0.25
Other Long-Term Liabilities	4.61	4.45	3.77	4.06	3.66	0.08
Total Liabilities	53	55.04	15.8	16.54	21.64	19.73

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.02	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	1,175	879.29	689.86	665.43	568.4	497.34
Retained Earnings	-694.87	-649.48	-561.39	-466.33	-377.88	-293.17
Comprehensive Income & Other	-6.04	-4.93	-4.97	-5	-5.23	-5.04
Total Common Equity	474.21	224.89	123.51	194.1	185.29	199.14
Shareholders' Equity	474.21	224.89	123.51	194.1	185.29	199.14
Total Liabilities & Equity	527.21	279.93	139.31	210.64	206.93	218.87

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	36.02	35.69	1.68	0.67	1.12	1.54
Net Cash (Debt)	290.26	237.77	130.21	197.14	183.76	188.77
Net Cash Growth	73.54%	82.60%	-33.95%	7.29%	-2.65%	-11.83%
Net Cash Per Share	2.30	2.70	1.83	3.70	3.92	4.57
Filing Date Shares Outstanding	194.52	130.07	77.01	70.9	49.28	42.92
Total Common Shares Outstanding	194.47	110.88	72.35	70.68	49.2	40.69
Working Capital	322.31	263.2	126.79	197.48	175.76	185.85
Book Value Per Share	2.44	2.03	1.71	2.75	3.77	4.89
Tangible Book Value	474.21	224.89	123.51	194.1	172.87	186.72
Tangible Book Value Per Share	2.44	2.03	1.71	2.75	3.51	4.59
Machinery	-	0.71	0.7	0.7	0.65	1.55
Leasehold Improvements	-	1.75	1.75	1.75	1.75	1.79

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error